Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study

Pharmacogenetics and Genomics

Volumn 24, Issue 4, 2014, Pages 185-194

  Barratt, Daniel T ^a   Bandak, Benedikte ^a,c   Klepstad, Pål ^d   Dale, Ola ^d   Kaasa, Stein ^e   Christrup, Lona L ^c   Tuke, Jonathan ^a   Somogyi, Andrew A ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^e European Palliative Care Research Center (PRC)   (Norway)

Author keywords

cancer; cytochrome P 450 CYP3A; fentanyl; pain management; pharmacogenetics; pharmacokinetics; transdermal patch

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; FENTANYL; FENTANYL DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN 1; NORFENTANYL; SERUM ALBUMIN; UNCLASSIFIED DRUG; ABC TRANSPORTER; ABCD1 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ARTICLE; BODY MASS; CANCER PAIN; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; HEREDITY; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VERY ELDERLY; CLINICAL TRIAL; COMPLICATION; GENETIC ASSOCIATION; GENETICS; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; PAIN; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSDERMAL PATCH; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; ATP-BINDING CASSETTE TRANSPORTERS; CYTOCHROME P-450 CYP3A; FEMALE; FENTANYL; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSDERMAL PATCH; YOUNG ADULT;

EID: 84896401779     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000032     Document Type: Article

References (49)

1. Van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007; 18:1437-1449.
2. Klepstad P, Kaasa S, Cherny N, Hanks G, de Conno F. Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network. Palliat Med 2005; 19:477-484.
3. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007; 81:429-444.
4. Ripamonti CI. Pain management. Ann Oncol 2012; 23 (Suppl 10): x294-x301.
5. Mather LE. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet 1983; 8:422-446.
6. McClain DA, Hug CC Jr. Intravenous fentanyl kinetics. Clin Pharmacol Ther 1980; 28:106-114.
7. Labroo RB, Paine MF, Thummel KE, Kharasch ED. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 1997; 25:1072-1080.
8. Schneider E, Brune K. Opioid activity and distribution of fentanyl metabolites. Naunyn Schmiedebergs Arch Pharmacol 1986; 334:267-274.
9. Wiesner G, Taeger K, Peter K. Serum protein binding of fentanyl. The effect of postoperative acute phase reaction with elevated alpha 1-acid glycoprotein and methodologic problems in determination by equilibrium dialysis. Anaesthesist 1996; 45:323-329.
10. Bower S. Plasma protein binding of fentanyl. J Pharm Pharmacol 1981; 33:507-514.
11. Wilson AS, Stiller RL, Davis PJ, Fedel G, Chakravorti S, Israel BA, et al. Fentanyl and alfentanil plasma protein binding in preterm and term neonates. Anesth Analg 1997; 84:315-318.
12. Henthorn TK, Liu Y, Mahapatro M, Ng KY. Active transport of fentanyl by the blood-brain barrier. J Pharmacol Exp Ther 1999; 289:1084-1089.
13. Park HJ, Shinn HK, Ryu SH, Lee HS, Park CS, Kang JH. Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clin Pharmacol Ther 2007; 81:539-546.
14. Takashina Y, Naito T, Mino Y, Yagi T, Ohnishi K, Kawakami J. Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system. Drug Metab Pharmacokinet 2012; 27:414-421.
15. Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther 1987; 240:159-166.
16. Varvel JR, Shafer SL, Hwang SS, Coen PA, Stanski DR. Absorption characteristics of transdermally administered fentanyl. Anesthesiology 1989; 70:928-934.
17. Yassen A, Olofsen E, Romberg R, Sarton E, Teppema L, Danhof M, et al. Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. Clin Pharmacol Ther 2007; 81:50-58.
18. Olkkola KT, Palkama VJ, Neuvonen PJ. Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology 1999; 91:681-685.
19. Kokubun H, Ebinuma K, Matoba M, Takayanagi R, Yamada Y, Yago K. Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain. J Pain Palliat Care Pharmacother 2012; 26: 98-104.
20. Saari TI, Laine K, Neuvonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Eur J Clin Pharmacol 2008; 64:25-30.
21. Elens L, van Gelder T, Hesselink DA, Haufroid V, van Schaik RH. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics 2013; 14:47-62.
22. Klepstad P, Fladvad T, Skorpen F, Bjordal K, Caraceni A, Dale O, et al. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain 2011; 152:1139-1145.
23. WHO. WHO's pain ladder for adults; 2013. Available at: http://www.who.int/cancer/palliative/painladder/en/. [Accessed 5 August 2013].
24. Karnofsky D, Abelmann W, Craver L, Burchenal J. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948; 1: 634-656.
25. Moksnes K, Fredheim OM, Klepstad P, Kaasa S, Angelsen A, Nilsen T, et al. Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference? Eur J Clin Pharmacol 2008; 64:497-502.
26. Galvan A, Fladvad T, Skorpen F, Gao X, Klepstad P, Kaasa S, et al. Genetic clustering of European cancer patients indicates that opioid-mediated pain relief is independent of ancestry. Pharmacogenomics J 2012; 12:412-416.
27. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
28. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
29. Levey A, Coresh J, Greene T, Marsh J, Kusek J, Lente Medicine F. Estimating glomerular filtration rate with a new equation: MDRD4 revised equation for use with IDMS-traceable serum creatinine. J Am Soc Nephrol 2005; 11:F-FC142.
30. Flockhart D. Drug interactions: cytochrome P450 Drug interaction table; 2007. Available at: http://medicine.iupui.edu/clinpharm/ddis/table.aspx. [Accessed 3 May 2013].
31. Venables W, Ripley B. Modern applied statistics with S. 4th ed. New York: Springer; 2002.
32. Lindeman R, Merenda P, Gold R. Introduction to bivariate and multivariate analysis. Glenview, IL: Scott, Foresman; 1980.
33. Gromping U. Relative importance for linear regression in R: the package relaimpo. J Stat Softw 2006; 17:1-27.
34. Tucker GT, Rostami-Hodjegan A, Jackson PR. Determination of drug-metabolizing enzyme activity in vivo: pharmacokinetic and statistical issues. Xenobiotica 1998; 28:1255-1273.
35. Klepstad P, Dale O, Kaasa S, Zahlsen K, Aamo T, Fayers P, et al. Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: a prospective survey in 300 adult cancer patients. Acta Anaesthesiol Scand 2003; 47:725-731.
36. Andreassen TN, Klepstad P, Davies A, Bjordal K, Lundstrom S, Kaasa S, et al. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. Eur J Clin Pharmacol 2011; 67:493-506.
37. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54:1271-1294.
38. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011; 11:274-286.
39. Zhang W, Yuan JJ, Kan QC, Zhang LR, Chang YZ, Wang ZY, et al. Influence of CYP3A5*3 polymorphism and interaction between CYP3A5*3 and CYP3A4*1G polymorphisms on post-operative fentanyl analgesia in Chinese patients undergoing gynaecological surgery. Eur J Anaesthesiol 2011; 28:245-250.
40. Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M, et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003; 38:978-988.
41. Heiskanen T, Matzke S, Haakana S, Gergov M, Vuori E, Kalso E. Transdermal fentanyl in cachectic cancer patients. Pain 2009; 144:218-222.
42. Kotlyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 1999; 37:8-19.
43. Solassol I, Bressolle F, Caumette L, Garcia F, Poujol S, Culine S, et al. Inter-and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. Ther Drug Monit 2005; 27:491-498.
44. Holdsworth MT, Forman WB, Killilea TA, Nystrom KM, Paul R, Brand SC, et al. Transdermal fentanyl disposition in elderly subjects. Gerontology 1994; 40:32-37.
45. Lotsch J, Walter C, Parnham MJ, Oertel BG, Geisslinger G. Pharmacokinetics of non-intravenous formulations of fentanyl. Clin Pharmacokinet 2013; 52:23-36.
46. Muijsers RB, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61:2289-2307.
47. Kokubun H, Matoba M, Hoka S, Yamada Y, Yago K. Relationship between serum fentanyl concentration and transdermal fentanyl dosage, and intra-individual variability in fentanyl concentration after application of fentanyl patches in patients with cancer pain. Jpn J Pharm Health Care Sci 2007; 33:200-205.
48. Solassol I, Caumette L, Bressolle F, Garcia F, Thezenas S, Astre C, et al. Inter-and intra-individual variability in transdermal fentanyl absorption in cancer pain patients. Oncol Rep 2005; 14:1029-1036.
49. Lane ME. The transdermal delivery of fentanyl. Eur J Pharm Biopharm 2013; 84:449-455.